A Oliver Sartor
Overview
Explore the profile of A Oliver Sartor including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
40
Citations
2175
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Barnett R, Jang A, Lanka S, Fu P, Bucheit L, Babiker H, et al.
Commun Med (Lond)
. 2024 Dec;
4(1):256.
PMID: 39623081
Background: Breast and prostate tumors are known to be less responsive to immune checkpoint inhibitors (ICIs). Tissue-based tumor mutation burden (tTMB) has emerged as a predictive biomarker of response to...
2.
Ross A, Zhang J, Huang H, Yamashita R, Keim-Malpass J, Simko J, et al.
Eur Urol Oncol
. 2024 Feb;
7(5):1024-1033.
PMID: 38302323
Background: Accurate risk stratification is critical to guide management decisions in localized prostate cancer (PCa). Previously, we had developed and validated a multimodal artificial intelligence (MMAI) model generated from digital...
3.
Tagawa S, Thomas C, Sartor A, Sun M, Stangl-Kremser J, Bissassar M, et al.
J Clin Oncol
. 2023 Nov;
42(7):842-851.
PMID: 37922438
Purpose: Novel therapies are needed to extend survival in metastatic castration-resistant prostate cancer (mCRPC). Prostate-specific membrane antigen (PSMA), a cell surface antigen overexpressed in PC, provides a validated target. This...
4.
Jang A, Lanka S, Jaeger E, Lieberman A, Huang M, Sartor A, et al.
JCO Precis Oncol
. 2023 Jul;
7:e2300131.
PMID: 37467457
Purpose: Circulating tumor DNA (ctDNA) detection in blood has emerged as a prognostic and predictive biomarker demonstrating improved assessment of treatment response in patients receiving immune checkpoint inhibitors (ICIs). Here,...
5.
Zimmerman R, Bilen M, Heath E, Nandagopal L, Swami U, Kessel A, et al.
Oncologist
. 2022 Aug;
27(10):e815-e818.
PMID: 36036607
Advanced prostate cancer (aPC) in Black men was reported to present with aggressive features and to be associated with poor prognosis. Herein, we compared the cell-free DNA (cfDNA) genomic landscape...
6.
Hall W, Karrison T, Rosenthal S, Amin M, Gomella L, Purdy J, et al.
Int J Radiat Oncol Biol Phys
. 2022 Jun;
114(2):266-274.
PMID: 35675855
Purpose: The immunoinflammatory state has been shown to be associated with poor outcomes after radiation therapy (RT). We conducted an a priori designed validation study using serum specimens from Radiation...
7.
Reyes D, Trock B, Tran P, Pavlovich C, Deville C, Allaf M, et al.
Med Oncol
. 2022 Apr;
39(5):63.
PMID: 35478055
Multimodal therapies were combined to eradicate the primary site, metastatic, and micrometastatic disease in men with newly diagnosed, synchronous, oligometastatic prostate cancer. The investigation included companion, phase II studies: total...
8.
Taza F, Holler A, Fu W, Wang H, Adra N, Albany C, et al.
JCO Precis Oncol
. 2021 Nov;
5.
PMID: 34778690
Methods: We conducted a multicenter retrospective analysis involving 12 sites. We collected genomic and clinical data from 123 patients with /-altered mCRPC who were treated with PARP inhibitors. The primary...
9.
10.
George D, Halabi S, Heath E, Sartor A, Sonpavde G, Das D, et al.
Cancer
. 2021 May;
127(16):2954-2965.
PMID: 33951180
Background: Retrospective analyses of randomized trials suggest that Black men with metastatic castration-resistant prostate cancer (mCRPC) have longer survival than White men. The authors conducted a prospective study of abiraterone...